OXACILLIN SODIUM (oxacillin sodium) by Bristol Myers Squibb is clinical pharmacology intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Approved for the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
Oxacillin sodium is a penicillinase-resistant penicillin administered intravenously for treatment of infections caused by penicillinase-producing staphylococci. It works by inhibiting bacterial cell wall biosynthesis, exerting bactericidal action against susceptible microorganisms during active multiplication. Peak serum levels are achieved approximately 5 minutes after intravenous injection with a half-life of 20–30 minutes.
Pre-launch status suggests limited immediate commercial opportunity; team focus will be on regulatory preparation, manufacturing scale-up, and launch readiness rather than established market activities.
CLINICAL PHARMACOLOGY Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V. administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20 to 30 minutes. Oxacillin sodium, with normal doses,…
Worked on OXACILLIN SODIUM at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Oxacillin Sodium offers exposure to pre-launch portfolio management, manufacturing scale-up, and reintroduction strategy within a legacy antibiotic space. Career growth depends on successfully executing launch activities and establishing market presence in a competitive, low-margin therapeutic category.